Refinement of newborn screening for cystic fibrosis with next generation sequencing
Pediatric Pulmonology · 2023-03 · 58 (3) · 778-787
DOI: 10.1002/ppul.26253 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Pulmonology, online erschienen am 05.12.2022. Verfasst von Michael J Rock und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Legacy of Angels Foundation.
Abstract (Originalsprache)
Background
Newborn screening for cystic fibrosis (CF) has been underway universally in the United States for more than a decade, as well in most European countries, and algorithms have been evolving throughout this period with quality improvement projects as immunoreactive trypsinogen (IRT) determinations alone have been transformed to a 2‐tier strategy with DNA analyses.
Objective
To apply next generation sequencing (NGS) as a screening method to expand the DNA tier and identify substantially more variants in the CF transmembrane conductance regulator ( CFTR ) gene to enhance sensitivity and equity while minimizing incidental findings.
Design
Sequential evaluation and improvement plan in three phases using algorithm modifications coupled to statewide follow up and analysis of screening outcomes.
Results
After demonstrating feasibility in the first phase, we studied an IRT/NGS algorithm that included CFTR Variants with Varying Clinical Consequences (VVCCs). This revealed a high identification of CF patients with 2‐variants detected through screening, but for every CF case there were 1.4 with CF metabolic syndrome/CF screen positive, inconclusive diagnosis (CRMS/CFSPID). This led us to a third phase of improvement in which the VVCCs were eliminated except for R117H, resulting in 94% 2‐variant detection of patients and 0.44:1 ratio of CRMS/CFSPID to CF.
Conclusion
NGS can be used with IRT as an effective method of identifying infants at risk for CF without an appreciable increase in detection of carriers. Its potential added value includes facilitating equity, enhancing sensitivity and detecting more CF patients with 2‐variants during the screening process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
- Newborn Screening Laboratory, Wisconsin State Laboratory of Hygiene, University of Wisconsin school of Medicine and Public Health, Madison, Wisconsin, USA.
- Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
ORCID-Profile: Michael J Rock, Nicholas Antos, Philip M Farrell
Förderung
- Legacy of Angels Foundation
Zitieren
APA
Rock, M. J., Baker, M., Antos, N., & Farrell, P. M. (2023). Refinement of newborn screening for cystic fibrosis with next generation sequencing. Pediatric Pulmonology, 58(3), 778-787. https://doi.org/10.1002/ppul.26253
Vancouver
Rock MJ, Baker M, Antos N, Farrell PM. Refinement of newborn screening for cystic fibrosis with next generation sequencing. Pediatric Pulmonology. 2023;58(3):778-787. doi:10.1002/ppul.26253
BibTeX
@article{Rock2023,
author = {Rock, Michael J and Baker, Mei and Antos, Nicholas and Farrell, Philip M},
title = {Refinement of newborn screening for cystic fibrosis with next generation sequencing},
journal = {Pediatric Pulmonology},
year = {2023},
volume = {58},
number = {3},
pages = {778--787},
doi = {10.1002/ppul.26253}
}
EUVIMED